According to a Pan American Health Organization (PAHO) and WHO joint press release, USAID “has tripled its financial support for the Pan American Health Organization/World Health Organization (PAHO/WHO) Regional Tuberculosis Program, which seeks to prevent 15,000 deaths from tuberculosis in Latin America and the Caribbean over the next five years and reduce the incidence of this disease.” The press release notes the commitment “increases a previous $5 million USAID/PAHO agreement, signed in November 2011 to strengthen programs for tuberculosis, maternal and neonatal health, and health systems in the region over the course of a three-year period, to a total of $8.9 million.” The press release states that $5.1 million is earmarked for the tuberculosis program, “up from an originally expected investment of $1.5 million” (10/31).
As part of its “Blueprint” series discussing the creation of a U.S. global AIDS blueprint called for by Secretary of State Hillary Clinton in July, the Center for Global Health Policy’s “Science Speaks” blog features an opinion piece by Salmaan Keshavjee of Harvard Medical School and Partners In Health. With an estimated 1,000 people with HIV dying of tuberculosis (TB) every day, “[i]t is clear that our current approaches to addressing the global tuberculosis pandemic are inadequate,” he writes. Keshavjee says, “First, bold targets for reducing tuberculosis incidence and zero TB-HIV deaths must be prioritized in the blueprint. … Second, known strategies for stopping the spread of tuberculosis have to be actively implemented. … Lastly, any effective strategy has to ensure that HIV advocates at the community level are educated about the threat of tuberculosis,” and he describes each of his points in detail. He concludes, “The United States has shown visionary leadership in the area of HIV treatment and changed the lives of countless people for the better. It is time to take on tuberculosis with the same moral and pragmatic vigor” (Barton, 10/31).
“Industrial pollution is putting the health of 125 million people at risk worldwide and is as dangerous in the developing world as malaria or tuberculosis, according to a new report,” titled “2012 World’s Worst Pollution Problems,” Reuters/ABC Science reports (Allen, 10/24). According to the Guardian, the report, published on Tuesday by the Blacksmith Institute in partnership with Green Cross Switzerland, “documents, for the first time, the public health impact of industrial pollutants — lead, mercury, chromium, radionuclides and pesticides — in the air, water and soil of developing countries.”
Speaking on Monday in Luanda, Angola, at the opening session of the inaugural meeting on Medical Education, sponsored by the Faculty of Medicine of Agostinho Neto University, WHO Regional Director for Africa Luis Gomes Sambo said communicable diseases account for 63 percent of deaths in Africa, with HIV and tuberculosis (TB) responsible for the majority of those, the Angola Press reports. Nonetheless, Africa has made significant progress against HIV/AIDS and malaria, as well as in improving child and maternal mortality, he said, according to the news service (10/22). Sambo also “said on Monday in Luanda that the population’s health depends on the provision of health care for those [in] need, as well as the efforts made by the society to protect, promote and re-establish the people’s well-being,” another article from Angola Press notes (10/23).
In a post in the Center for Global Health Policy’s “Science Speaks” blog, Lucica Ditiu, executive secretary of the Stop TB Partnership, examines the need to include tuberculosis (TB) in the global AIDS response blueprint that Secretary of State Hillary Clinton announced at the XIX International AIDS Conference (AIDS 2012), writing, “At present one in four AIDS-related deaths is precipitated by TB. … All people living with HIV need to get tested for TB and receive TB treatment if they have the disease.” She continues, “We urge PEPFAR to include in the blueprint explicit TB/HIV indicators and activities,” and she provides five examples (10/23).
“An antibiotic used to treat severe bacterial infections showed promise at treating a highly drug-resistant and deadly form of tuberculosis [TB],” according to a study conducted by U.S. government and South Korean researchers and published in the New England Journal of Medicine on Wednesday, Reuters reports (Steenhuysen, 10/17). The “small study offers a bit of cautious optimism about the prospects for treatment of tuberculosis, … showing that adding a 12-year-old antibiotic called linezolid, brand name Zyvox, to existing treatments cured nearly 90 percent of patients with a form of tuberculosis resistant to both first- and second-line antibiotics,” NPR’s “Shots” blog writes (Knox, 10/18). “However, most of the patients [in the study] — 82 percent — experienced side effects while on the treatment, which tempered the findings, the team reported,” Reuters notes. “Researchers are desperately looking for new treatments for drug-resistant forms of TB, which threatens to derail progress in the global fight to eradicate the disease,” according to the news agency (10/17).
Noting the release of the WHO Global Tuberculosis Report 2012 this week, this Lancet editorial says the results show “good and bad news.” The editorial says, “The number of tuberculosis cases and deaths continues to fall … and overall, the world is on track to achieve the global target of a 50 percent reduction by 2015.” However, “with an estimated 8.7 million new cases (of which 13 percent represent co-infections with HIV) and 1.4 million deaths from tuberculosis in 2011,” the “global burden of tuberculosis remains huge,” the editorial states. The report also shows “alarming levels of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis,” the editorial notes.
Number Of New TB Infections Fall, But Drug Resistance, Lack Of Funding Could Slow Progress, WHO Reports
“New tuberculosis [TB] infections dropped 2.2 percent worldwide last year, but with nearly nine million new infections, the World Health Organization said TB remains a massive problem that could worsen if countries shortchange funding to fight it,” Reuters reports (Steenhuysen, 10/17). “In a new report issued Wednesday, the U.N. agency estimated there were about 8.7 million new cases of TB last year, down from about 8.8 million in 2010,” and “[t]he number of deaths was unchanged at about 1.4 million — making it the second-leading killer among infectious diseases after AIDS,” the Associated Press writes (Cheng, 10/17). “The number of people becoming ill with tuberculosis has been falling steadily for roughly a decade after a surge in the 1990s,” but “those numbers are still huge, and only 19 percent of those infected with forms of the disease that are resistant to multiple tuberculosis drugs are being diagnosed, the WHO estimated,” according to the Wall Street Journal (McKay, 10/18). BBC News notes the report “warned of ‘persistently slow progress’ in treating tuberculosis which is resistant to antibiotics” (Gallagher, 10/17).
“Researchers will find out early next year whether the first new vaccine against tuberculosis [TB] for 90 years protects against a disease that was once neglected but is now resurgent worldwide,” Financial Times reports. “Helen McShane, professor of vaccinology at Oxford University, said on Monday that clinical trial results of the MVA85A vaccine — developed in her laboratory over 10 years at a cost of Â£30 million [$48 million] — would be known in the first quarter of 2013,” the newspaper writes (Cookson, 10/15). “Today, most babies in the world are immunized with the old Bacille Calmette-Guerin (BCG) vaccine, first used in 1921,” PlusNews/IRIN writes. “Oxford’s vaccine, known as MVA85A, is designed to boost the effects of BCG,” the news service adds (10/16).
The Wall Street Journal examines how bureaucracy in India is slowing the treatment of tuberculosis (TB) in the country. The newspaper recounts the story of Rahima Sheikh, “one of 16 patients identified by Mumbai doctors to be resistant to virtually all traditional TB treatments.” The Wall Street Journal writes, “Mumbai officials have publicly pledged free treatment for Mrs. Sheikh and other, similar patients with extreme forms of drug resistance within the city’s jurisdiction,” but “Mrs. Sheikh has now become caught in the bureaucracy of India’s incomplete national network for treating the most virulent TB.”